ArticleVirology journal2025
Molecular docking insights of Nigella sativa compounds as potential antiviral inhibitory agents against the replication-machinery proteins VPg and RdRP in rabbit hemorrhagic disease virus (RHDV).
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Rabbit Hemorrhagic Disease Virus (RHDV) represents a significant threat to rabbit populations globally, affecting both wild and domesticated rabbits, with mortality rates ranging from 50% to 90%. Despite its severity, there is currently no specific treatment available for RHDV. This study investigates the potential of natural compounds derived from Nigella sativa as antiviral agents against RHDV. Molecular docking analysis was conducted to explore the interaction between eleven compounds from Nigella sativa and the two key proteins of RHDV, viral protein genome-linked (VPg) and RNA-dependent RNA polymerase (RdRP), as key proteins involved in viral replication. Explicit-solvent MD (100 ns, 310 K) was performed for four top complexes (VPg/RdRP with nigellidine and dithymoquinone), tracking backbone/ligand RMSD, radius of gyration, H-bond counts, and per-residue RMSF, with equilibrated frames analyzed by PCA and MM-GBSA. The results revealed successful docking of all compounds from Nigella sativa to both VPg and RdRP proteins. From Nigella sativa compounds, Nigellidine and Dithymoquinone displayed strong interactions with VPg and RdRP and formed various hydrogen bonds and hydrophobic interactions, indicating their potential as inhibitors of viral replication. Interestingly, all ligands demonstrated favorable drug-likeness properties, adhering to Lipinski's Rule of Five and exhibiting desirable pharmacokinetic profiles. Thymohydroquinone and nigellidine displayed the highest lipophilicity, suggesting their potential for efficient tissue penetration and distribution. Complexes remained stable and retained poses, with reduced pocket flexibility, favorable MM-GBSA ΔG_bind, and tighter PCA clustering-supporting sustained binding and pocket stabilization. These findings suggest that compounds from Nigella sativa show promise as natural antiviral agents against RHDV. Nevertheless, additional experimental validation through in vitro and in vivo studies is essential to confirm the effectiveness and safety of these compounds for treating RHDV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.